key: cord-0299373-n0v65i5g
authors: Stoner, M. C. D.; Angulo, F. J.; Rhea, S.; Brown, L. M.; Atwell, J. E.; Nguyen, J. L.; McLaughlin, J.; Swerdlow, D. L.; MacDonald, P. D. M.
title: Estimates of presumed population immunity to SARS-CoV-2 by state in the United States, August 2021
date: 2021-09-21
journal: nan
DOI: 10.1101/2021.09.17.21263759
sha: 5899db6752d7a236e78ce046d1e275d5252413a5
doc_id: 299373
cord_uid: n0v65i5g

Background: Information is needed to monitor progress toward a level of population immunity to SARS-CoV-2 sufficient to disrupt viral transmission. We estimated the percentage of the United States (US) population with presumed immunity to SARS-CoV-2 due to vaccination, natural infection, or both as of August 26, 2021. Methods: Publicly available data as of August 26, 2021, from the Centers for Disease Control and Prevention (CDC) were used to calculate presumed population immunity by state. Seroprevalence data were used to estimate the percentage of the population previously infected with SARS-CoV-2, with adjustments for underreporting. Vaccination coverage data for both fully and partially vaccinated persons were used to calculate presumed immunity from vaccination. Finally, we estimated the percentage of the total population in each state with presumed immunity to SARS-CoV-2, with a sensitivity analysis to account for waning immunity, and compared these estimates to a range of population immunity thresholds. Results: Presumed population immunity varied among states (43.1% to 70.6%), with 19 states with 60% or less of their population having been infected or vaccinated. Four states have presumed immunity greater than thresholds estimated to be sufficient to disrupt transmission of less infectious variants (67%), and none were greater than the threshold estimated for more infectious variants (78% or higher). Conclusions: The US remains a distance below the threshold sufficient to disrupt viral transmission, with some states remarkably low. As more infectious variants emerge, it is critical that vaccination efforts intensify across all states and ages for which the vaccines are approved.

In mid-2021, the Delta variant (B.1.617.2), a World Health Organization variant of concern (VOC), [2] became the predominant SARS-CoV-2 variant circulating in the US. Associated with we then compared these estimates with a range of potential thresholds needed to achieve population-level immunity.

Using publicly available data, we employed a three-step process to calculate presumed population immunity by state ( Figure 1 ) and (4) not immune. Categories 1-3 were combined to create a group of individuals with "presumed immunity." Our final estimate represents the total population by state meeting criteria for this composite category. Lastly, we compared these estimates with a range of potential values for the population immunity threshold to determine how close each state may be to achieving population immunity. [6] [7] [8] [9] 13] To estimate the number of people previously infected with SARS-CoV-2 by state, we followed Angulo and colleagues' methods.

[14] Specifically, we obtained the most recent seroprevalence data for a given state from the Centers for Disease Control and Prevention (CDC) Nationwide . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint was <1, the multiplier was set at 1 to equal the number of reported cases. Lastly, we estimated the number of infections in the population on August 26, 2021, the most recent date at the time of analysis, by multiplying the cumulative number of infections on that day from CDC by the underreporting multiplier. We divided this number by the total population to derive the percentage of the total population with immunity due to infection as of August 26, 2021.

To determine how many people may have presumed immunity through vaccination, we used estimates of the percentage fully vaccinated and the percentage who had received at least one dose of a two-dose regimen, as reported by CDC on August 26, 2021.

[1] We calculated the percentage immune from full vaccination by multiplying the total population fully vaccinated with each approved COVID-19 vaccine by the estimated protection against infection for Janssen . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint We then calculated the number who had received only one dose of Moderna or Pfizer-BioNTech vaccine by subtracting those who were fully vaccinated from those with at least one dose and multiplied this number by estimated protection from one dose of a two-dose vaccine (82%)[23].

Next, we multiplied the percentages of persons immune from full vaccination (by any type of COVID-19 vaccine) and partial vaccination by the total population and added them together. We divided this number by the total population to estimate the percentage of the total population with vaccine-derived immunity as of August 26, 2021.

To determine the percentage of the total population in each state with some immunity due to vaccination, infection, or both, we defined immunity in the population based on four mutually exclusive categories: immune due to both vaccination and infection, immune due to vaccination only, immune due to infection only, and not immune. We calculated the percentage of the population in each category by multiplying the percentages with some immunity due to natural infection and vaccination. The four categories sum to 100% of the population. Finally, we added the percentages with immunity due to both infection and immunity, infection only, and vaccination only to get the percentage of the total population of each state with some immunity due to vaccination and/or infection as of August 26, 2021.

We conducted a sensitivity analysis to explore the effect of waning immunity from natural infection and from vaccination. For waning immunity from natural infection, we used CDC data[1] on the number of reported COVID-19 cases per day to estimate the proportion of the reported infections that occurred >12 months before August 26, 2021 (i.e., as of the end of August 2020), 6-12 months before August 26, 2021 (i.e., as of the end of February 2021), and <6

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted September 21, 2021. ; 1 0 months before August 26, 2021.

[1] For those infected during these time periods, we estimated immunity of 25%, 50%, and 100%, respectively. For waning immunity from vaccination, we used vaccine uptake data from the CDC[1] to estimate the proportion of the fully vaccinated who, as of August 26, 2021, had been fully vaccinated for ≥ 5 months (i.e., before the end of March 2021 ) and <5 months (i.e., after the end of March 2021).

[1] For those who had been vaccinated for ≥ 5 months, we assumed vaccine efficacy of 65%.

The final estimate of the percentage of persons with presumed immunity due to COVID-19 vaccination or SARS-CoV-2 infection by state was compared with estimates of the population immunity threshold from the literature to assess each state's progress toward population immunity. We used a range of potential thresholds, from a minimum of 67% to a maximum of 90% based on a range of R 0 of the virus of 3 to 10, with the most likely number being ~3 for early variants (67%) and 4.5 for more infectious variants (78%), although the R 0 and corresponding threshold for the Delta variant is likely higher than 78%.[6-10,13,24,25] If future VOCs arise that are more transmissible, the R 0 could be higher, leading to an even higher threshold.

As of August 26, 2021, the percentage of the total population previously infected with SARS-CoV-2 by state ranged from 4.0% in Hawaii to 41.7% in Mississippi ( Figure 2 ). The percentage vaccinated for COVID-19 ranged from 35.5% in Idaho to 61.5% in Massachusetts. Comparisons among the four categories indicated that the people with immunity due to vaccination only represented the largest proportion of the population (Table 1) and ranged from 22.1% in Mississippi to 57.7% in Hawaii. In the second category, the percentage of the population with . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted September 21, 2021. ; 1 1 presumed immunity due to both vaccination and infection ranged from 2.4% in Hawaii to 18.1% in Illinois and 18.0% in New Jersey. The states with the highest percentages of immunity due to both infection and vaccination were those where a large percentage of the population had been previously infected (e.g., 31.5% in New Jersey, 33.7% in Illinois). In the third category, the percentage with presumed immunity by infection only and not vaccination ranged from 1.6% in Hawaii to 25.9% in Mississippi. States with a high percentage of immunity due to infection only had relatively low or modest vaccination rates (e.g., 37.9% in Mississippi). In the fourth category, the percentage without immunity from either vaccination or infection ranged from 29.4% in New Jersey to 56.9% in Idaho. States with the highest percentages of the population without immunity had some of the lowest vaccination rates (e.g., 39.0% in West Virginia, 35.5% in Idaho,). In 19 states, ≥ 40% of the population had no immunity to SARS-CoV-2.

The overall percentage of each state with presumed immunity due to either vaccination or infection ranged from 43.1% in Idaho to 70.6% in New Jersey (Figure 3 ). Using a minimum threshold of 67% corresponding to an R 0 of 3, only four states would have reached population immunity (New Jersey, Illinois, Maryland, Pennsylvania).[6-9,13] Based on a higher R 0 of 4.5 for more infectious variants (78% threshold), no states would have reached the population immunity threshold as of August 26, 2021.[6-9,13] Given that the threshold for the Delta variant is likely even higher than 78%, we can assume that no states will have reached that

In the sensitivity analysis assessing the impact of waning immunity, we estimated that the percentage with presumed immunity due to either vaccination or infection would be lower than originally calculated and would range from 37.9% in Idaho to 62.3% in New Jersey (Table 2) , and none of the states would meet even the minimum threshold of 67%.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted September 21, 2021. ; https://doi.org/10.1101/2021.09.17.21263759 doi: medRxiv preprint

We found that the estimated proportion of the population with presumed immunity to SARS-CoV-2 as of August 26, 2021, varied substantially by state in the US. The states with the highest levels of immunity were those with the highest vaccination rates or those with modest vaccination rates but large proportions immune by infection. While four states may have reached thresholds for population immunity based on less infectious variants (67%), we estimated that none of the states would have reached population immunity for more infectious variants (78% or higher) as of August 26, 2021. As variants that are more infectious may continue to emerge, it is critical that we continue to monitor and intensify vaccination efforts across all states.

The number of states with a high proportion of the population with no presumed immunity to SARS-CoV-2 is high, with proportions reaching >50% in four states and ≥ 40% in 19 states. The findings with no presumed immunity to SARS-CoV-2 portend continued cases, hospitalizations, and large outbreaks of COVID-19. Further, after accounting for waning immunity, we found that presumed immunity may be even lower, which would lead to an even higher likelihood for sustained transmission than in our original calculations.

With the low levels of presumed immunity in many states, increasing the immunity of the population by vaccinating children will be important. In 2019, 14.6% of the US population was aged <12 years. [26] Achieving population immunity levels >75% for the entire population (all ages) will be difficult without achieving substantial immunity in children.

There were several limitations to our approach. First, we used data from CDC's Nationwide Commercial Laboratory Seroprevalence Surveys because they provide nucleocapsid seroprevalence estimates for each state. As these surveys use blood samples submitted for . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted September 21, 2021. ; https://doi.org/10.1101/2021.09.17.21263759 doi: medRxiv preprint reasons unrelated to COVID-19 (e.g., routine clinical visits), they might not be representative of the broader U.S. population. Specifically, people who have blood samples taken during routine medical care or sick visits sought health care and had a blood test and, therefore, may differ in their overall health and disease exposure risk from the general US population.

[16] If these individuals are more likely to have other conditions or exposures that also put them at increased risk for COVID-19, this could result in a higher seroprevalence estimate from the survey population being applied to the general US population in our analysis.

Second, although we conducted a sensitivity analysis to explore the potential impact of waning immunity, we were unable to more precisely account for waning immunity after infection or vaccination due to a lack of data on date of infection and limited information about duration of natural immunity. Emerging data suggest that immunity due to infection and vaccination may wane over time and may depend on factors including individual characteristics and the SARS-CoV-2 variant. Although this could result in an overestimate of immunity in our calculations (both primary and sensitivity analyses), our use of recent seroprevalence data should be a reasonably accurate and up-to-date proxy for current immunity in the population. Third, to calculate the percentage of the population with immunity, we assumed that immunity due to infection and vaccination were independent. It is possible that vaccination status might vary by infection status, if individuals who had experienced COVID-19 were more or less likely to seek vaccination than those who had not. We were unable to find representative estimates in the literature describing this relationship. Fourth, this was a cross-sectional analysis, conducted at a single point in time, and therefore could not incorporate changes over time or newer emerging variants. A more comprehensive model would be needed to incorporate these additional factors.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Lastly, there are limitations with conducting this analysis at the state level. We were unable to identify relevant seroprevalence estimates by county, and substantial heterogeneity in both disease incidence and vaccine uptake exists for numerous reasons, including population characteristics, population density, and vaccine acceptance. While overall immunity at the larger population levels is critical, the ability to control transmission is also highly dependent on local levels of immunity (e.g., within cities and communities). Geographic clustering of low vaccination rates and/or limited natural immunity will provide opportunities for sustained transmission. In summary, the percentage of the population with presumed immunity varied substantially across the United States as of August 26, 2021. States with the highest calculated levels of presumed immunity had the highest vaccination rates. A small number of states had population immunity over the minimum threshold for less infectious variants (67%), but no states were estimated to have reached population immunity using a threshold for more infectious variants (78% or higher) at the time of this analysis. A third or greater of the population in all states have neither vaccine-derived nor natural immunity to SARS-CoV-2; therefore, it is imperative that vaccination efforts intensify within all states and that uptake occurs across all ages as soon as vaccines are available. Tracking variation among states and counties is important for public health response and ensuring that resources are targeted to communities at the highest risk of amplified SARS-CoV-2 transmission. Without increased population immunity, risk of continued transmission and large outbreaks will exist throughout the US.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint F  i  g  u  r  e  2  .  P  e  r  c  e  n  t  a  g  e  o  f  t  h  e  p  o  p  u  l  a  t  i  o  n  (  A  )  p  r  e  v  i  o  u  s  l  y  S  A  R  S  -C  o  V  -2  i  n  f  e  c  t  e  d  a  n  d  (  B  )  v  a  c  c  i  n  a  t  e  d  f  o  r  C  O  V  I  D  -1  9  b  y  s  t  a  t  e  a  s  o  f  A  u  g  u  s  t  2  6  ,  2  0  2 

.

It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review) F  i  g  u  r  e  1  .  P  r  o  c  e  s  s  f  o  r  c  a  l  c  u  l  a  t  i  n  g  p  e  r  c  e  n  t  a  g  e  o  f  t  h  e  p  o  p  u  l  a  t  i  o  n  v  a  c  c  i  n  a  t  e  d  f  o  r  C  O  V  I  D  -1  9  o  r  p  r  e  v  i  o  u  s  l  y   S  A  R  S  -C  o  V  -2  i  n  f  e  c  t  e  d  b  y  s  t  a  t  e  a  s  o  f  A  u  g  u  s  t  2  6  ,  2  0 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted September 21, 2021. ;

WHO. Tracking SARS-CoV-2 variants. 2021. Available at